Association of IL28B SNP With Progression of Egyptian HCV Genotype 4 Patients to End Stage Liver Disease by El-Awady, Mostafa K. et al.
KOWSAR
                            www.HepatMon.com
Association of IL28B SNP With Progression of Egyptian HCV Genotype 4 
Patients to End Stage Liver Disease
Mostafa K. El-Awady 1*, Lotiaf Mostafa 2, Ashraf A. Tabll 1, Tawfeek H. Abdelhafez 1, Noha 
G Bader El Din 1, Naglaa Zayed 3, Reem El Shenawy 1, Yasmin El Abd 1, Reham M. Hasan 1, 
Hosam Zaghlol 4, Hesham El Khayat 5, Ashraf O. Abdel Aziz 3 
1 Department of Microbial Biotechnology, National Research Center, Giza, Egypt
2 Ahmed Maher Educational Hospital, Cairo, Egypt
3 Department of Tropical Medicine and Hepatology Kasr El Aini Cairo University, Cairo, Egypt
4 Faculty of Medicine, Mansoura University, Mansoura, Egypt
5 Theodor Bilharz Research Institut, Cairo, Egypt
Hepat Mon.2012;12(4):271-277. DOI: 10.5812/hepatmon.835
ARTICLE INFO ABSTRACT
Article history:
Received: 26 Dec 2011
Revised: 20 Jan 2012
Accepted: 01 Feb 2012
Keywords:
Hepatitis C
Interleukin 28B
Polymorphism, Genetic
Liver Cirrhosis
Carcinoma, Hepatocellular
Article type:
Original Article
Background: IL28B single nucleotide polymorphisms (SNPs) play important roles in the 
management of hepatitis C virus (HCV) infections and are strongly associated with spon-
taneous and treatment-induced HCV clearance.
Objectives: In the present study, the association between IL28B variants and the progres-
sion of HCV infection in Egyptian patients infected with type 4a virus will be examined. 
Patients and Methods: Frequencies of the protective genotype C/C of SNP, rs12979860 
were determined in healthy subjects, spontaneous resolvers, and chronic HCV type 4 pa-
tients with low F scores and in patients with end stage liver disease (ESLD). This study in-
cluded a total of 404 subjects.  Patients infected with HCV type 4a (n = 304) were divided 
into; chronic hepatitis C (CHC) with low F scores (CHC, n = 110), end stage liver disease 
(n = 110), liver cirrhosis (LC) (n = 35) and  hepatocellular carcinoma (HCC) patients (n = 
75), spontaneous resolvers of HCV infection (n = 84) were also included. A healthy group 
representing the Egyptian population (n = 100) was also included in the genotyping of 
IL28B. The later was typed via a polymerase chain reaction based restriction fragment 
length polymorphism (PCR-RFLP) assay analysis on purified genomic DNA extracted 
from all individuals. 
Results: A significant increase (P < 0.0005) was observed in frequencies of IL-28B 
rs12979860 C/C genotypes in the healthy population, than in the CHC, LC and HCC groups 
(C/C = 48%, 13%, 0%.and 0% respectively). On the other hand the C/C genotype was signifi-
cantly higher (P < 0.0005) in spontaneous resolvers than in healthy subjects. A compa-
rable significant increase in the frequency of C/T allele accompanied by mild elevation of 
T/T allele frequency, were detected along the progression towards ESLD. 
Conclusions: Genotype C/C is associated with viral clearance during acute infection. The 
sharp decline in the C/C genotype from healthy to CHC subjects and the total absence 
of the C/C genotype in ESLD suggests a central role of this genotype against HCV disease 
progression. Copyright  c 2012 Kowsar Corp. All rights reserved. 
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 Implication for health policy/practice/research/medical education:
Chronic HCV patients (CHC) can be roughly categorized into patients with a very slow disease progression and patients with rapid 
progression into LC and HCC. The factors controlling the pathobiology of HCV disease are either viral or host related. This study 
will shed light on the    association between IL28B variants and the progression of HCV infection in Egyptian patients infected with 
type 4a virus.
1. Background
Several immunological factors have been implicated in 
determining disease outcomes in hepatitis C virus (HCV) 
infections (1, 2). Approximately 30% of individuals clear 
the infection naturally, whereas the remaining 70% de-
velop chronic disease that may result in liver cirrhosis 
(LC) and/or hepatocellular carcinoma (HCC) (3, 4). There-
fore, identification of the factors involved in persistent 
HCV infections may lead to the development of effective 
prognostic tests and hence improved treatment man-
agement or to the development of novel antiviral agents. 
Although the role of the adaptive immune response has 
been well documented (2), other evidence (5, 6) supports 
a role for the innate immune system in regulating dis-
ease progression in HCV infection. More recent evidence 
to support a role for the innate immune system in HCV 
outcomes, has come from a series of studies on SNPs in 
the IL28B gene region which predicts spontaneous and 
type 1 IFN induced clearance of HCV infections. Multiple 
genome-wide association studies (GWAS) have identi-
fied single nucleotide polymorphisms (SNPs) near the 
IL28B gene (encoding IFN-λ3) to be strongly associated 
with spontaneous and treatment-induced clearance of 
HCV infections (7). One of these SNPs, rs12979860 (8) was 
pivotal in predicting the resolution of HCV infections (9, 
10). The SNP rs12979860 is found ~ 3 kb upstream from 
the IL28B gene. Little is known about the IFN λ family, but 
evidence is mounting to support a role for them in the 
immune response to viral infections (11, 12). Therefore, 
associations made between IL28B variants and HCV clear-
ance in large-scale genetic studies provides an exciting 
mechanistic link between innate immunity and viral 
clearance. Chronic HCV patients (CHC) can be roughly 
categorized into patients with a very slow disease pro-
gression and patients with rapid progression into LC and 
HCC. The factors controlling the pathobiology of HCV 
disease are either viral or host related. No apparent dif-
ferences between the pathobiology of HCV genotypes 
was reported until Mihm et al. (13) identified a relation-
ship between hepatic steatosis and HCV genotype 3 infec-
tions. This relationship was subsequently confirmed by 
comparing patients infected with genotype 3 and those 
infected with other genotypes (14-16). However, Genotype 
4a represents more than 93 % of chronic HCV patients in 
Egypt (17, 18). 
2. Objectives
The aim of the present study is to examine the associa-
tion between IL28B variants and the progression of HCV 
infection in Egyptian patients infected with type 4a vi-
rus. The incidence of the protective genotype C/C of SNP, 
rs12979860 located ~ 3 Kb upstream of the IL 28B gene 
was screened in healthy Egyptian subjects, chronically 
infected HCV patients with low F scores, spontaneous re-
solvers and in HCV type 4a patients with LC or HCC.
3. Patients and Methods
Serum α fetoprotein levels were routinely tested in all 
patients with decompensated cirrhosis. AFP levels were 
generally elevated in cases that were proved to be HCC, 
however, the levels ranged from 15 to 650 ng/ml. The di-
agnosis of HCC was confirmed by a 4 phase multidetec-
tor computed tomography (CT) scan or dynamic con-
trast enhanced magnetic resonance imaging (MRI) 
3.1. Patients
a) Healthy subjects (n = 100, 50 males and 50 females) 
with no history of liver infection, long term drug use, 
autoimmune hepatitis or alcohol consumption were 
selected. Age of the healthy subjects ranged from 18-64 
years with a median value of 41 years.
b) Spontaneous resolvers (84 subjects; 53 males and 31 
females) who tested positive for IgG anti HCV Abs (3rd 
generation) and negative for HCV RNA, were enrolled in 
the study.
c) Chronic HCV patients (n = 110, 85 males and 25 fe-
males, age 22-65 years with a median value of 43.5 years) 
with limited pathogenesis, i.e. mild, elevated or normal 
hepatic enzymes. All chronic HCV patients had mild liver 
disease F0-F2, HAI1 - HAI6 according to the METAVIR his-
tological liver biopsy grading. Patients with diabetes, 
thyroid dysfunction, coinfection with HIV or hepatic 
pathogens such as; HBV DNA, CMV DNA, and Anti schisto-
somiasis Abs were excluded.
d) Decompensated cirrhosis  patients (n = 35, 22 males 
and 13 females, aged 31-62 years with a median value of 
46.5 years) with end stage live disease (ESLD) due to 
chronic HCV type 4a infection without the involvement 
of other hepatic factors such as; auto immune hepatitis, 
hepatitis B virus (HBV), alcohol hepatotoxicity, or a histo-273 Hepat Mon. 2012;12(4)
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Table 1. Distribution of IL28B rs12979860 SNP Alleles and C: T Ratios a
CC, No. (%) CT, NO. (%) TT, No. (%) C:T ratio, %
Healthy (n = 100) 48 (48) 38 (38) 14 (14) 67 : 33
SL (n = 110). 72 (86) 6 (7) 6 (7) 89.5 : 10.5 
CHC (n = 110) 14 (13) 83 (75) 13 (12) 50 : 50 
ESLD (n = 110 ) 0.0 (0.0) 88 (80) 30 (20) 40 : 60 
a IL28B single nucleotide polymorphisms (SNPs) was typed via a polymerase chain reaction based restriction fragment length polymorphism (PCR-RFLP) 
-BstU1 analysis on purified genomic DNA extracted from all individuals
Table 2. Chi-squared and Hardy-Weinberg Equilibrium Testing of IL28B Genotype Distribution in Different Outcomes of HCV Infection, i.e. Spontaneous 
Clearance, Persistent Infection and End Stage Liver Disease as Compared With Healthy Controls
Patient group X2 a Genotype Expected Observed C Allele Frequency T Allele Frequency
Control 1.98 CC
CT
TT
44.89
44.22
10.89
48
38
14
0.67 0.33
Spontaneous Clearance 39.38 CC
CT
TT
80.1
18.8
1.1
86
7
7
0.9 0.11
Chronic HCV  25.02 CC
CT
TT
25.5
50
24.5
13
75
12
0.51 0.5
ESLD 44.44 CC
CT
TT
16
48
36
0
80
20
0.4 0.6
a Chi-squared, the X2 value indicates the difference between expected and observed values for genotype counts
ry of aflatoxin hepatotoxicity. Some patients were suffer-
ing from ascites, or esophageal bleeding with no hepatic 
focal lesions.
e) Hepatocellular carcinoma patients (n = 75, 57 males 
and 18 females, aged 34-67 years with a median value of 
50.5 years) with multiple lesions and a history of liver 
cirrhosis on top of a chronic HCV infection. None of the 
patients had any other hepatopathogenic etiology. The 
diagnosis of HCC was made after reviewing images gen-
erated with several imaging modalities. Nodules larger 
than 1 cm found in the ultrasound screening of a cirrhot-
ic liver were investigated further with either 4phase mul-
tidetector computed tomography (CT) scan or dynamic 
contrast enhanced magnetic resonance imaging (MRI). If 
the appearances were typical of HCC, namely, hypervas-
cular in the arterial phase with washout in the portal ve-
nous or delayed phase, the lesion was diagnosed as HCC. 
If the findings were not characteristic or the vascular 
profile was not typical, a second contrast enhanced study 
with the other imaging modality was performed or the 
lesion was biopsied. All patients were confirmed not to 
have other cancers in an initial screening examination.
3.2. Detection of IL-28B rs12979860 C/T Polymorphism
3.2.1. Samples
Peripheral blood on EDTA was withdrawn from all sub-
jects and genomic DNA was extracted using genomic 
DNA extraction kits (Qiagen, Milan Italy). Plasma were 
separated before DNA extraction and utilized for testing; 
HBV sAg, anti schistosomiasis Abs and autoimmune Abs 
(ANA, AMA, LKA). Since CMV reactivation was recently 
shown by our laboratory to interfere with several in-
nate immunity pathways and subsequently poor drug 
induced viral clearance rates (19), CMV DNA was tested in 
extracted DNA from all subjects to exclude subjects with 
detectable CMV DNA from the study.  Three different healthy individuals were typed and the products were run 
on agarose gel electrophoresis (4%) to resolve restricted fragments after 
bstU1 digestion. 139 bp indicates TT genotype, 109 bp indicates CC geno-
type, 139 + 109 bp indicates CT genotype
Figure 1. PCR- RFLP Analysis of rs 12979860 IL28B SNP Using an Assay De-
scribed in Materials and Methods.274 Hepat Mon. 2012;12(4)
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3.2.2. Genotyping for the IL-28B rs12979860 C/T Polymor-
phism
Genotyping for the IL-28B rs12979860 C/T polymor-
phism was performed by a polymerase chain reaction 
based restriction fragment length polymorphism (PCR-
RFLP) assay. Genomic DNA was extracted from whole 
blood samples by means of the QIAamp DNA blood mini 
kit (Qiagen, Milan, Italy) according to the manufacturer’s 
instructions. A 139 base pair (bp) product was obtained 
with the forward primer 5`- CCAGGGCCCCTAACCTCT-
GCA - 3` and the reverse primer 5`- GGGAGCGCGGAGT-
GCAATTCA - 3`, newly designed with the aid of the NCBI 
Primer-Blast Tool (http://www.ncbi.nlm.nih.gov/tools/
primer-blast/).  PCR amplification was carried out in a to-
tal volume of 10 ul containing 10 mM Tris–HCl (pH 8.3), 50 
mM KCl, Tween-20 0.01%, 0.2 mM deoxyribonucleotides, 
2–4 pmol of each primer, 2.0 mM MgCl2, 0.5 units hot-
start Taq DNA polymerase (Right Taq, Euroclone, Milan, 
Italy). Samples containing 10 ng of genomic DNA were 
subjected to 35 cycles of denaturation (at 95 0C for 60 s), 
annealing (at 64 0C for 60 s), and elongation (at 72 0C for 
60 s). Ten ul of the amplicons were digested with 1 unit 
of the BstU-I restriction endonuclease (New England Bio-
labs, Hitchin, UK) in a total volume of 20 ul at 37°C over-
night.  The fragments were resolved by electrophoresis 
on 4% agarose gel after staining with ethidium bromide. 
A band of 139 bp indicates the T/T genotype, 109 bp + 30 
bp (usually invisible on the gel) indicates the C/C geno-
type, and 139 bp + 109 bp+ 30 bp (invisible) indicates the 
C/T genotype (Figure 1). 
3.3. Statistical Analysis 
All statistical analyses were performed using the SPSS 
9.0 statistical software program. A statistical significance 
was considered when P ≤ 0.05. IL28B SNP genotype analy-
sis was carried out according to Santiago Rodriguez, Tom 
R. Gaunt and Ian N. M. Day, with the Hardy-Weinberg 
Equilibrium Testing of Biological Ascertainment for 
Mendelian Randomization Studies. American Journal of 
Epidemiology Advance Access published on January 6, 
2009, DOI 10.1093/aje/kwn359. http://www.oege.org/soft-
ware/hwe-mr-calc.shtml
4. Results
4.1. Genotyping of IL28B in Healthy Subjects
To type the rs 12978860 SNP among the healthy Egyp-
tian population, the C/T polymorphism was determined 
in a sample of 100 subjects that had neither a history of 
viral hepatitis infection nor other chronic inflammatory 
diseases that may reflect poor innate subject immunity. 
As demonstrated in Figure 2 the protective genotype C/C 
constituted 48% of the studied sample, while the T/T gen-
otype constituted 14 % and the heterozygous genotype 
C/T 38%. The genotype analysis of the SNP revealed that 
the protective C allele was significantly more prevalent 
than the T allele (67% C vs. 33% T) in a total of 200 alleles 
(100 subjects) tested in the present study.
4.2. IL 28 C/C Frequency in Spontaneous Resolvers of 
HCV Infection
To test the hypothesis, do patients who spontaneously 
clear HCV infection during or shortly following the acute 
phase bear the protective C/C genotype more frequent-
ly than other groups studied, i.e. healthy, CHC, LC and 
HCC patients, we typed the IL28 B SNP (rs 12979860) in 
84 subjects with a spontaneous clearance of their HCV 
infection, i.e. detectable HCV Ab and negative HCV RNA 
in their sera. The results clearly indicated the protective 
role of the C/C genotype in patients who spontaneously 
cleared the virus, where C/C represented 86% of sponta-
neous resolvers vs. 48, 13, 0 and 0% in healthy subjects, 
CHC, LC and HCC patients respectively (Figure 2).
4.3. IL28B Variants in Chronic HCV Patients
The results of IL28B typing in 110 chronic HCV patients 
with a low F score (F0-F2) regardless of their response 
to pegylated IFN + RBV combined therapy are depicted 
in Table 1 and Figures 2 and Figure 3. A sharp decrease in 
the incidence of the protective C/C genotype and C allele 
Il28B SNP was typed among healthy, chronic hepatitis C (CHC), cirrhotic 
and hepatocellular carcinoma (HCC) patients. The frequencies of IL28B 
variants were represented as % of total number of subjects in each group
Healthy population (n = 100), chronic hepatitis C (CHC; n = 110), liver cir-
rhosis (LC; n = 35) and hepatocellular carcinoma (HCC; n = 75)
Figure 2. Frequency of rs12979860 C/C in all 320 Study Participants.
Figure 3. Frequencies of rs12979860 C/C, C/T, T/T.275 Hepat Mon. 2012;12(4)
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compared with the typing data of healthy subjects was 
observed, 13 % C/C in CHC vs. 48% C/C in healthy subjects 
and 50% C allele in CHC vs. 67% C allele in healthy subjects. 
Such a decline in the C/C genotype was not reflected in a 
comparable increase in the T/T genotype; however a two 
fold increase (75% vs. 38%) in the heterozygous genotype 
C/T was observed in the CHC group compared with the 
healthy subjects. 
4.4. Typing of IL28B in HCV Patients With End Stage Liv-
er Disease (ESLD)
The results of IL28B typing in ESLD (LC and HCC) are de-
picted in Table 1 and Figures 2 and Figure 3. The most inter-
esting results of the current study are the entire absence 
of the protective C/C genotype in HCV patients with ESLD. 
The IL28B typing profile in this patient cohort displayed a 
clear inversion of C to T ratios to become 40%:60% instead 
of 67%:33% found in healthy subjects and 50%:50% in CHC 
patients. It is clear from the data presented in Figure 3 
that ratios of both the C/C and C/T genotypes in different 
cohorts were exchanged as the progression of the HCV 
disease takes place, i.e. the C/C genotype continues to de-
cline till it reaches its lowest value in the ESLD patients, 
while the C/T genotype continues to increase, progress-
ing till it reaches its peaks in the ESLD group with no 
significant change in the incidence of the T/T genotype. 
Of the four patient groups, IL28B rs 12979860 genotypes 
were observed to have a statistically significant associa-
tion with the outcomes of HCV infections (Table 2).
5. Discussion
As a result of the powerful genetic approach genome-
wide association study (GWAS), hundreds of thousands 
of SNPs spanning all chromosomes were mapped to 
distinct phenotypes or traits (20). Several studies have 
linked the IL28B SNP rs 12979860 to treatment induced as 
well as spontaneous clearance of HCV infections. Mem-
bers of the interferon lambda group such as IL28B and 
IL 29, both use the JAK-STAT signal cascade in a similar 
fashion to interferon-α and induce interferon stimu-
lated genes, ISGs (21, 22). The later have been shown to 
play an important role in HCV treatment outcomes and 
spontaneous clearance of the virus (22). Whether IL 28B 
plays a role in supporting innate immunity against 
severe pathogenesis, either via control of viral replica-
tion or through independent pathways to halt the dis-
ease progression is not yet clear. The current study was 
conducted to examine whether the C/C  genotype of rs 
12979860 SNP, located in the promoter region  ~ 3 kb  up-
stream of the IL28B gene, a member of the IFN λ innate 
control gene family, is significantly reduced in the Egyp-
tian population infected with HCV type 4a and suffering 
from advanced liver pathobiology. We hypothesized that 
genotype C/C of the IL28B is associated with an inherited 
tendency towards protection against the progressive de-
velopment of ESLD (LC and HCC). Spontaneous clearance 
of the HCV occurs in only 15–50% of all HCV infected indi-
viduals, while the majority of patients develop a chronic 
infection. Thomas et al. (8) found that IL28B rs12979860 
is strongly associated with the chance to clear HCV spon-
taneously in populations of African or European ances-
try, with an approximately three times higher clearance 
rate in individuals with the rs12979860 genotype C/C 
versus C/T, T/T. In the present study IL28B SNP was care-
fully typed into four distinct cohorts; namely healthy 
Egyptian subjects, spontaneous resolvers with detect-
able HCV Abs and undetectable HCV RNA, chronic HCV 
type 4a patients with F0-F2 fibrosis and a fourth group 
of ESLD due to HCV type 4a infection (decompensated LC 
and HCC). Genotyping of IL28B rs 12979860 in a sample 
of the normal Egyptian population (representing major 
ethnic backgrounds; Caucasian whites, Nubians, Bedou-
ins and Egyptian Copts) revealed that the C/C genotype 
comprises the highest incidence; (48%) compared with 
the other two genotypes T/T (14%) and C/T (38%). The C:T al-
lele ratio in the studied healthy subjects is 67:33, a figure 
that puts Egypt in the middle between the highest ratios 
found in populations from Asian and the lowest ratio in 
populations with African ancestry. Several global stud-
ies revealed that the C/C genotype is the major player in 
drug induced viral clearance, while both the C/T and T/T 
genotypes have a poor association with clearance rates 
(23-25). The frequency distribution of rs 12979860 SNP 
with C/C approximating 50% is closest to the Turkish 
population among the frequencies reported in diverse 
populations worldwide. This incidence rate is supported 
historically in light of the long (400 year) Ottoman occu-
pation in Egypt and the high incidence of interbreeding 
between the two populations. These data indicate that 
unlike populations with African ancestry, there are no 
genetic barriers among the Egyptian HCV patients pro-
hibiting the control of HCV infections. 
IL-28B rs12979860 C/T polymorphism appeared to pre-
dict the rate of spontaneous clearance of HCV infections, 
which could be observed in the 53.0% of patients with 
a C/C genotype vs. 23.4% of patients with a T/T genotype 
(8). In the present study, the observed decline in C/C fre-
quency among chronic HCV patients vs. healthy subjects 
(13% vs. 48%) highlights the protective role of IL28B C/C 
against progression to chronic infection via spontane-
ous clearance of the virus during the acute phase. A com-
parable increase in the T/T genotype was not observed 
in CHC patients indicating other factors are involved in 
viral persistence during progression to a chronic state. 
The current data shows that the decline observed in the 
C/C genotype was replaced by a corresponding increase 
in the frequency of the heterozygous C/T genotype, thus 
suggesting that phenotypic expression of the T allele 
is dominant over the C allele in heterozygous patients. 
The simultaneous decline of the C/C genotype frequency 
to one quarter of the value in healthy subjects and dou-276 Hepat Mon. 2012;12(4)
IL28B SNP Predicts Disease Progression of HCV Type 4 Infections El-Awady MK et al.
bling of the C/T genotype in CHC patients have brought 
the C:T ratio to equivalence (50%:50%). The current high 
frequency of C/C in subjects with spontaneous clearance 
of the HCV is compatible with the protective role of the 
C/C genotype against viral persistence. Recently, Fabris 
et al. (25) reported that in patients with chronic HCV in-
fections, carriage of the T/T genotype occurred more fre-
quently in those patients affected by ESLD than in those 
with mild chronic hepatitis, thus supporting the results 
of the present study.  The present data also supports im-
portant recent results demonstrating that IL-28B poly-
morphisms are linked to a better response to antiviral 
treatment in patients with HCV chronic hepatitis (21, 
26, 27) and to a higher probability of clearing the virus 
during the natural history of a chronic HCV infection (7, 
8). In logical terms, the C/C genotype seems to be under-
represented among patients with ESLD since carriage of 
the rs12979860 C/C genotype protects from unfavorable 
outcomes in chronic viral hepatitis C. In conclusion; in 
IL-28B rs12979860 C/T polymorphism the T allele appears 
to be more prevalent in patients with ESLD (LC and HCC). 
Besides, the C/C genotype is protective against the devel-
opment of chronic HCV infection as well as later at the 
final stages of the disease, either directly or via its role 
in inhibiting HCV replication leading in most instances 
to spontaneous or IFN induced viral clearance during the 
early stages of infection.
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